SCHEMBL14627397

SCHEMBL14627397

CON=C1[CH]CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14627396 1.00
SCHEMBL2642420 0.93
SCHEMBL17582047 0.80
SCHEMBL13167839 0.71
SCHEMBL28246303 0.71
SCHEMBL1929947 0.69
SCHEMBL1929946 0.69
SCHEMBL30550937 0.67 GRM5 (0.45)
SCHEMBL14404551 0.67 GRM5 (0.45)
SCHEMBL13167838 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357718-B2 N-heterocyclyl- or cycloalkyl-N-(2-carboxy-5-aryl-3-thiophenyl)cycloalkanecarboxamides, e.g., 5-(3-fluorophenyl)-3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-thiophene-2-carboxylic acid; especially for prevention and treatment of HVC VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2013-01-22 US claimed
CN-100413861-C Compounds and methods for the treatment or prevention of flavivirus infections VIROCHEM PHARMA INC (CA) 2008-08-27 CN claimed